Granted Patent
B2
US 12,544,358 · App. 18/130,246 · Granted Feb 10, 2026
Enhancing autophagy or increasing longevity by administration of urolithins
Inventors:
Christopher L. Rinsch (Lausanne, CH); William Blanco-Bose (La Croix, CH); Bernard Schneider (Pully, CH); Laurent Mouchiroud (Morges, CH); Dongryeol Ryu (Renens, CH); Penelope Andreux (Eclepens, CH); Johan Auwerx (Buchillon, CH)
Assignee:
Amazentis SA
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Disclosed are methods, compounds, and compositions useful for increasing autophagy and promoting longevity. The methods, compounds, and compositions relate to urolithins and urolithin precursors and use thereof. Certain urolithins are represented by Formula I, while certain urolithin precursors are represented by Formula IV. The urolithin may be urolithin A, urolithin B, urolithin C, or urolithin D. The urolithin precursor may be ellagic acid or an ellagitannin. The methods include in vivo, ex vivo, and in vitro uses of the compounds and compositions.
Claims (19)
1 . A composition, comprising urolithin A or a pharmaceutically acceptable salt thereof; and a second ingredient selected from the group consisting of resveratrol and coenzyme Q10; wherein the coenzyme Q10 is ubiquinol or ubiquinone.
2 . The composition of claim 1 , wherein the second ingredient is resveratrol.
3 . The composition of claim 1 , wherein the second ingredient is coenzyme Q10; and the coenzyme Q10 is ubiquinol.
4 . The composition of claim 1 , wherein the second ingredient is coenzyme Q10; and the coenzyme Q10 is ubiquinone.
5 . The composition of claim 1 , further comprising a pharmaceutically acceptable carrier.
6 . A method of improving or increasing mitochondrial function, comprising administering to a vertebrate in need thereof an effective amount of the composition of claim 1 .
7 . The method of claim 6 , wherein the mitochondrial function is mitophagy.
8 . The composition of claim 2 , further comprising a pharmaceutically acceptable carrier.
9 . The composition of claim 3 , further comprising a pharmaceutically acceptable carrier.
10 . The composition of claim 4 , further comprising a pharmaceutically acceptable carrier.
11 . A method of improving or increasing mitochondrial function, comprising administering to a vertebrate in need thereof an effective amount of the composition of claim 2 .
12 . The method of claim 11 , wherein the mitochondrial function is mitophagy.
13 . A method of improving or increasing mitochondrial function, comprising administering to a vertebrate in need thereof an effective amount of the composition of claim 3 .
14 . The method of claim 13 , wherein the mitochondrial function is mitophagy.
15 . A method of improving or increasing mitochondrial function, comprising administering to a vertebrate in need thereof an effective amount of the composition of claim 4 .
16 . The method of claim 15 , wherein the mitochondrial function is mitophagy.
17 . The composition of claim 2 , wherein the composition is in the form of a dietary supplement or a nutraceutical.
18 . The composition of claim 3 , wherein the composition is in the form of a dietary supplement or a nutraceutical.
19 . The composition of claim 4 , wherein the composition is in the form of a dietary supplement or a nutraceutical.
Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 18, 2023
From: SCHNEIDER, BERNARD; AUWERX, JOHAN; MOUCHIROUD, LAURENT; RYU, DONGRYEOL; ANDREUX, PENELOPE
To: ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL)
Reel/Frame 063685/0845 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 18, 2023
From: RINSCH, CHRISTOPHER L.; BLANCO-BOSE, WILLIAM
To: AMAZENTIS SA
Reel/Frame 063695/0045 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 18, 2023
From: ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL)
To: AMAZENTIS SA
Reel/Frame 063695/0048 →
Continuity (6)
Provisional Application
61791137
· Mar 15, 2013
Provisional Application
61712886
· Oct 12, 2012
Provisional Application
61665137
· Jun 27, 2012
References Cited (287)
US 5073545A
· Arima et al.
· 1991
[cited by applicant]
US 6066312A
· Egawa et al.
· 2000
[cited by applicant]
US 6133311A
· Bok et al.
· 2000
[cited by applicant]
US 6440436B1
· Ghosal
· 2002
[cited by applicant]
US 8183282B2
· Seeram et al.
· 2012
[cited by applicant]
US 8894993B2
· Ghosal
· 2014
[cited by applicant]
US 8933217B2
· Rinsch et al.
· 2015
[cited by applicant]
US 9394269B2
· Rinsch et al.
· 2016
[cited by applicant]
US 9573922B2
· Rinsch et al.
· 2017
[cited by applicant]
US 9872850B2
· Rinsch et al.
· 2018
[cited by applicant]
US 9962366B2
· Rinsch et al.
· 2018
[cited by applicant]
US 9980980B2
· Rinsch et al.
· 2018
[cited by applicant]
US 9994542B2
· Rinsch et al.
· 2018
[cited by applicant]
US 20030078212A1
· Li et al.
· 2003
[cited by applicant]
US 20050282781A1
· Ghosal
· 2005
[cited by applicant]
US 20060257337A1
· Sherris
· 2006
[cited by applicant]
US 20080039179A1
· Seelig et al.
· 2008
[cited by applicant]
US 20100004334A1
· Jouni et al.
· 2010
[cited by applicant]
US 20100055247A1
· Tirrito
· 2010
[cited by applicant]
US 20100298249A1
· Moutet et al.
· 2010
[cited by applicant]
US 20110263521A1
· Moutet et al.
· 2011
[cited by applicant]
US 20160095881A1
· Sen
· 2016
[cited by applicant]
US 20180015069A1
· Rinsch et al.
· 2018
[cited by applicant]
US 20180256471A1
· Rinsch et al.
· 2018
[cited by applicant]
US 20180256538A1
· Rinsch et al.
· 2018
[cited by applicant]
US 20180296464A1
· Graban et al.
· 2018
[cited by applicant]
US 20190000867A1
· Rinsch et al.
· 2019
[cited by applicant]
US 20200085895A1
· Patel et al.
· 2020
[cited by applicant]
US 20210210190A1
· Rinsch et al.
· 2021
[cited by applicant]
US 20210251869A1
· Rinsch et al.
· 2021
[cited by applicant]
US 20210346342A1
· Rinsch et al.
· 2021
[cited by applicant]
US 20220280410A1
· Perretta et al.
· 2022
[cited by applicant]
US 20230277669A1
· Rinsch et al.
· 2023
[cited by applicant]
US 20230301890A1
· Rinsch et al.
· 2023
[cited by applicant]
US 20230355501A1
· Ookura et al.
· 2023
[cited by applicant]
US 20230390238A1
· Rinsch et al.
· 2023
[cited by applicant]
US 20240148690A1
· Andreux et al.
· 2024
[cited by applicant]
US 20240156777A1
· Rinsch et al.
· 2024
[cited by applicant]
US 20240366558A1
· Rinsch et al.
· 2024
[cited by applicant]
US 20250049750A1
· Rinsch et al.
· 2025
[cited by applicant]
US 20250161391A1
· Rinsch et al.
· 2025
[cited by applicant]
US 20250213524A1
· Rinsch et al.
· 2025
[cited by applicant]
US 20250228817A1
· Rinsch et al.
· 2025
[cited by applicant]
CN 101301319A
· 2008
[cited by applicant]
CN 101484125A
· 2009
[cited by applicant]
CN 103442594A
· 2013
[cited by applicant]
CN 109316478A
· 2019
[cited by applicant]
CN 110368476A
· 2019
[cited by applicant]
CN 112843049A
· 2021
[cited by applicant]
CN 113171319A
· 2021
[cited by applicant]
CN 113476362A
· 2021
[cited by applicant]
CN 113855758A
· 2021
[cited by applicant]
CN 114794490A
· 2022
[cited by applicant]
CN 116889583A
· 2023
[cited by applicant]
EP 2033526A1
· 2009
[cited by applicant]
EP 2068864A2
· 2009
[cited by applicant]
JP H02304080A
· 1990
[cited by applicant]
JP 2008503456A
· 2008
[cited by applicant]
JP 2010280627A
· 2010
[cited by applicant]
JP 2016216378A
· 2016
[cited by applicant]
JP 2017007951A
· 2017
[cited by applicant]
JP 2017014154A
· 2017
[cited by applicant]
JP 2017019725A
· 2017
[cited by applicant]
JP 2017031108A
· 2017
[cited by applicant]
WO WO200006134A2
· 2000
[cited by applicant]
WO WO0015044A1
· 2000
[cited by applicant]
WO WO0149281A2
· 2001
[cited by applicant]
WO WO2002094984A2
· 2002
[cited by applicant]
WO WO2005077899A2
· 2005
[cited by applicant]
WO WO2005097106A1
· 2005
[cited by applicant]
WO WO2006007310A2
· 2006
[cited by applicant]
WO WO2006127832A2
· 2006
[cited by applicant]
WO WO2007101247A2
· 2007
[cited by applicant]
WO WO2007127263A2
· 2007
[cited by applicant]
WO WO2008016554A1
· 2008
[cited by applicant]
WO WO2007133249A3
· 2009
[cited by applicant]
WO WO2009031023A2
· 2009
[cited by applicant]
WO WO2009120799A2
· 2009
[cited by applicant]
WO WO2009153652A2
· 2009
[cited by applicant]
WO WO2010118419A2
· 2010
[cited by applicant]
WO WO2011011721A2
· 2011
[cited by applicant]
WO WO2012088519A2
· 2012
[cited by applicant]
WO WO2012103487A1
· 2012
[cited by applicant]
WO WO2012113835A1
· 2012
[cited by applicant]
WO WO2014004902A2
· 2014
[cited by applicant]
WO WO2015100213A2
· 2015
[cited by applicant]
WO WO2017109195A1
· 2017
[cited by applicant]
WO WO2019168972A1
· 2019
[cited by applicant]
WO WO2021237214A1
· 2021
[cited by applicant]
WO WO2023031673A1
· 2023
[cited by applicant]
WO WO2023237926A2
· 2023
[cited by applicant]
WO WO2024246601A1
· 2024
[cited by applicant]
WO WO2024246603A1
· 2024
[cited by applicant]
WO WO2025078619A1
· 2025
[cited by applicant]
Ratman et al Journal of Neuroscience and Biotechnology, 2009, 9, 6741-6746 (Year: 2009).
[cited by examiner]
Chen et al Am J Physiol Endocrinol. Metab, 2011, 301, E853-E863 (Year: 2011).
[cited by examiner]
Gonzalez-Sarrias et al British Journal of Nutrition, 2010, 104, 503-512 (Year: 2010).
[cited by examiner]
Hipkiss, “Aging, proteotoxicity, mitochondria, glycation, NAD+ and carnosine: possible inter-relationships and resolution of the oxygen paradox”, Frontiers in aging neuroscience: 10 (2010).
[cited by applicant]
Rubinsztein et al., “Autophagy and aging”, Cell 146(5): 682-695 (2011).
[cited by applicant]
Adams et al., “Pomegranate Ellagitannin-Derived Compounds Exhibit Antiproliferative and Antiaromatase Activity in Breast Cancer Cells In Vitro,” Cancer Prev Res, 3: 108-113 (2010).
[cited by applicant]
Andreaux et al., “Appendix A: The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans,” Nature Metabolish, 1:595-603 (2019).
[cited by applicant]
Andreaux et al., “The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans,” Nature Metabolish, 1:595-603 (2019).
[cited by applicant]
Berry Health Benefits Symposium (2009 Berry Health Benefis Symposium).
[cited by applicant]
Bhattacharyya et al., “Beneficial Effect of Processed Shilajit on Swimming Exercise Induced Impaired Energy Status of Mice,” Pharmacologyonline, 1: 817-825 (2009).
[cited by applicant]
Bhattacharyya et al., “Shilajit Dibezno-a-Pyrones: Mitochondria Targeted Antioxidants,” Pharmacologyonline, 2: 690-698 (2009).
[cited by applicant]
Bialonska, et al., “Urolithins, Intenstinal Microbial Metabolites of Pomegranate Ellagitannins, Exhibit Potent Antioxidant Activity in a Cell-Based Assay,” J Agric Food Chem, 57(21); 10181-10186, 2009.
[cited by applicant]
Cerda et al., “Repeated oral administration of high doses of the pomegranate ellagitannin punialagin to rats for 37 days is not toxic,” J. Agric. Food Chem., 51(11):3493-3501 (2003).
[cited by applicant]
Chen et al., “Coordination of Autophagy and the Proteasome in Resolving Endoplasmic Reticulum Stress,” Veterinary Pathology 48(1):245-253 (2011).
[cited by applicant]
Chen, T. et al., “Rapamycin and other longevity-promoting compounds enhance the generation of mouse induced pluripotent stem cells”,
[cited by applicant]
De Meyer et al., “Autophagy in the cardiovascular system,” Biochimica et Biophysica Acta 1793: pp. 1485-1495 (2009).
[cited by applicant]
Dr. Mark Percival, “Antioxidants,” Clinical Nurtition Insights, 1998.
[cited by applicant]
Du et al., “Starving Neurons Show Sex Difference in Autophagy,” The Journal of Biological Chemistry, 284(4): 2383-2396 (2009).
[cited by applicant]
Ghosal et al., “Effects of shilajit and its active constituents on learning and memory in rats,” Phytotherapy Res, 7(1): 29-34 (1993).
[cited by applicant]
Ghosal et al., “Shilajit. Part 4. Chemistry of Two Bioactive Benzopyrone Metabolites,” J Chem Research (S), 11: 350-351 (1989).
[cited by applicant]
Gimenez-Bastida J. A. et al., “Ellagitannin metabolites, urolithin A glucuronide and its aglycone urolithin A, ameliorate TNF-induced inflammation and associated molecular markers in human aortic endothelial cells,” Mol…
[cited by applicant]
Gulcin et al., “Antioxidant and Antiradical Activities of L-carnitine,” Life Sciences, 78: 803-811 (2006).
[cited by applicant]
International Search Report and Written Opinion from corresponding PCT application PCT/US2013/048310 dated Jan. 22, 2014.
[cited by applicant]
Ishimoto H. et al., “In vivo anti-inflammatory and antioxidant properties of ellagitannin metabolite urolithin A.” Bioorg Med Chem Lett, 21(19): 5901-5904 (2011).
[cited by applicant]
Johanningsmeier et al., “Pomegranate as a Functional Food and Nutraceutical Source” Annu. Rev. Food Sci. Technol, 2:181-201 (2010).
[cited by applicant]
Kasimsetty, S. G. et al., “Colon Cancer Chemopreventive Activities of Pomegranate Ellagitannins and Urolithins”,
[cited by applicant]
Kiss, A. K. et al., “Epigenetic modulation of mechanisms involved in inflammation: Influence of selected polyphenolic substances on histone acetylation state”,
[cited by applicant]
Landete, J. M., “Ellagitannins, ellagic acid and their derived metabolites: A review about source, metabolism, functions and health”,
[cited by applicant]
Larossa, M. et al., “Anti-inflammatory properties of a pomegranate extract and its metabolite urolithin-A in a colitis rat model and the effect of colon inflammation on phenolic metabolism”,
[cited by applicant]
Lin et al., “Pharmacological Promotion of Autophagy Alleviates Steatosis and Injury in Alcoholic and Non-alcoholic Fatty Liver Conditions in Mice,” J Hepatol. May 2013; 58(5):993-999.
[cited by applicant]
Liu et al., “Appendix C: Impact of Urolithin A vs Placebo Supplementation on Muscle Endurance and Mitochondrial Health in the Elderly: A Randomized Clinical Trial,” Manuscript Draft.
[cited by applicant]
Manach et al., “Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies
[cited by applicant]
Markaki et al., “Modeling human diseases in Caenorhabditis elegans,” Biotechnol J, 5:1261-1276 (2010).
[cited by applicant]
Mingorance et al., “Critical update for the clinical use of L-carnitine analogs in cardiometabolic disorders,” Vascular Health and Risk Management, 7:169-176 (2011).
[cited by applicant]
Reuter et al., “Carnitine and Acylcarnitines Pharmacokinetic, Pharmacological and Clinical Aspects,” Clin Pharmacokinet, 51 (9): 553-572 (2012).
[cited by applicant]
Saul, N. et al., “Diversity of Polyphenol Action in Caenohabditis elegans: Between Toxicity and Longevity”,
[cited by applicant]
Seeram, N. P. et al., “Pomegranate Ellagitannin-Derived Metabolites Inhibit Prostate Cancer Growth and Localize to the Mouse Prostate Gland”,
[cited by applicant]
Silverman et al., “Modeling molecular and cellular aspects of human disease using the nematode caenorhabditis elegans,” Pediatric Research, 65(1):10-18 (2009).
[cited by applicant]
Singh et al., “Appendix B: Urolithin A improves leg muscle strength, exercise performance and mitochondrial health in a proof-of-concept clinical trial in overweight adults,” Manuscript Draft.
[cited by applicant]
Stout et al., “Mitochondria's Role in Skin Ageing,” Biology, 8(29): 12 pages (2019).
[cited by applicant]
Uchida, “Pathologic Changes and Autophagy: New Insights for the Pathogenesis of Animal Diseases,” Veterinary Pathology 54(6):881-884 (2017).
[cited by applicant]
Verzelloni E. et al., “Antiglycative and neuroprotective activity of colonderived polyphenol catabolites.” Mol. Nutr. Food Res, 55(1):35-43 (2011).
[cited by applicant]
Zenjun et al., “Distribution of Ellagic Acids in Plantae and Thier Bioactivies,” Natural Product Research and Development, 22:519-524 and 540 (2010).
[cited by applicant]
Extended European Search Report for EP Application No. 23175506.7 dated Jan. 8, 2023.
[cited by applicant]
Friedman et al., “NSAIDs in Dermatologic Therapy: Review and Preview.” J Cutan Med Surg 2002, 6(5):449-59.
[cited by applicant]
Gonzalez-Sarrias et al., “NF-?B-dependent anti-inflammatory activity of urolithins, gut microbiota ellagic acid-derived metabolites, in human colonic fibroblasts.” British Journal of Nutrition 2010, 104, 503-512.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/EP24/80149 dated Jan. 29, 2025.
[cited by applicant]
Liu et al., “Chemical constituents of Panax ginseng and Panax notoginseng explain why they differ in therapeutic efficacy.” Pharmacological Research 161 (2020): 105263.
[cited by applicant]
Ndiaye et al., “The grape antioxidant resveratrol for skin disorders: promise, prospects, and challenges.” Arch Biochem Biophys 2011, 508(2) 164-170.
[cited by applicant]
Nolan et al., “Over-the-Counter Topical Skincare Products: A Review of the Literature.” Journal of Drugs in Dermatology, 2012, 11(2), 220-224.
[cited by applicant]
Search Report for GB Application No. 2316295.1 dated Apr. 18, 2024.
[cited by applicant]
Wang et al., “Gut microbial transformation, a potential improving factor in the therapeutic activities of four groups of natural compounds isolated from herbal medicines.” Fitoterapia 138 (2019): 104293.
[cited by applicant]
Abstract of unexamined Japanese application No. JP2010-280627 published Dec. 16, 2010.
[cited by applicant]
Basu et al., “Pomegranate juice: A heart-healthy fruit juice,” Nutr Rev, 67(1): 49-56 (2009).
[cited by applicant]
Bishayee, “Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials.” Cancer Prevention Research 2(5) (2009): 409-418.
[cited by applicant]
Bonetto et al., “Are antioxidants useful for treating skeletal muscle atrophy?.” Free Radical Biology and Medicine 47 (2009): 906-916.
[cited by applicant]
Brummer et al., “Particle Characterisation in Excipients, Drug Products and Drug Substances” SGS Life Science Services, Issue 11: 6 pages (2008).
[cited by applicant]
Cerda et al., “Identification of Urolithin A as a metabolite produced by human colon microflora from ellagic acid and related compounds,” J Agric Food Chem, 53(14): 5571-5576 (2005).
[cited by applicant]
Cerda et al., “Pomegranate juice supplementation in a chronic obstructive pulmonary disease: a 5-week, randomized, double-blind, placebo-controlled trial,” Eur J Clin Nutr, 60: 245-253 (2006).
[cited by applicant]
Chaudhary et al., “Enhancement of solubilization and bioavailability of poorly soluble drugs by physical and chemical modifications: A recent review,” Journal of Advanced Pharmacy Education & Research, 2(1):32-67 (2012).
[cited by applicant]
Curto et al., “Inhibitors of mammalian melanocyte tyrosinase: in vitro comparisons of alkyl esters of gentisic acid with other putative inhibitors,” Biochem Pharmacol, 57:663-672 (1999).
[cited by applicant]
Dell'agli, et al., “Ellagitannins of fruit rind of pomegranate (
[cited by applicant]
Eisenberg et al., “Induction of autophagy by spermidine promotes longevity.” Nature Cell Biology 11(11) (2009): 1305-1314.
[cited by applicant]
Ertam et al., “Efficiency of ellagic acid and arbutin in melasma: A randomized, prospective, open-label study,” Journal of Dermatology, 35: 570-574 (2008).
[cited by applicant]
Esmaillzadeh et al., “Concentrated pomegranate juice improves lipid profiles in diabetic patients with hyperlipidemia,” J Med Food, 7(3): 305-308 (2004).
[cited by applicant]
Espín et al., “Iberian pig as a model to clarify obscure points in the bioavailability and metabolism of ellagitannins in humans,” J Agric Food Chem, 55(25): 10476-10485 (2007).
[cited by applicant]
Extended European Search Report for EP Application No. 25157187.3 dated Aug. 5, 2025.
[cited by applicant]
Farris, “The anti-aging effects of niacinamide” Dermatology Times, [online] Oct. 14, 2015<https://www.dermatologytimes.com/view/anti-aging-effects-niacinamide>.
[cited by applicant]
Hartman et al., “Pomegranate juice decreases amyloid load and improves behavior in a mouse model of Alzheimer's disease”, Neurobiology of Disease, 24(3):506-515 (Elsevier Inc., St. Louis, MO 2006).
[cited by applicant]
Hu et al., “Efficacy and comparative effectiveness of sirolimus as an anticancer drug.” The Laryngoscope 121(5) (2011): 978-982.
[cited by applicant]
IN Application No. 392/CHE/2004 A (DSM IP Assets BV [NL]), filed Apr. 28, 2004.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/EP25/065409 dated Jun. 3, 2025.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US11/67229 dated Jul. 25, 2024.
[cited by applicant]
Kadowaki et al., “Nutrient control of macroautophagy in mammalian cells.” Molecular Aspects of Medicine 27.5-6 (2006): 426-443.
[cited by applicant]
Kannappan et al., “Neuroprotection by spice-derived nutraceuticals: you are what you eat!.” Molecular Neurobiology 44(2) (2011): 142-159.
[cited by applicant]
Larrosa et al., “Ellagitannins, ellagic acid and vascular health”, Molecular Aspects of Medicine, 31(6):513-539 (Pergamon Press, Oxford, Great Britain, Dec. 1, 2010).
[cited by applicant]
Lee et al., “b-Secretase (BACE1) Inhibitors from Sanguisorbae Radix”, Arch. Pharm. Res., 28(7):799-803 (Korea, 2005).
[cited by applicant]
Li et al., “EGCG stimulates autophagy and reduces cytoplasmic HMGB1 levels in endotoxin-stimulated macrophages.” Biochemical Pharmacology 81(9) (2011): 1152-1163.
[cited by applicant]
Liu et al. “Antiaging effects of urolithin A on replicative senescent human skin fibroblasts”, Rejuvenation Research, 22(3): 191-200 (2019).
[cited by applicant]
NIH, “What Is Atherosclerosis?” NHLBI, National Institutes of Health (2016).
[cited by applicant]
Pandya et al., “Disorders of Hyperpigmentation,” New and Emerging Therapies, 18(1): 91-98 (2000).
[cited by applicant]
Park et al., “Micronization of arbutine using supercritical anti-solvent,” Korean Journal of Chemical Engineering, 25(3): 581-584 (2008).
[cited by applicant]
Partial European Search Report for European Application No. 17186188.3 dated Oct. 27, 2017.
[cited by applicant]
Patel et al., “A review of the use of biotin for hair loss.” Skin Appendage Disorders 3 (2017): 166-169.
[cited by applicant]
Paula's choice skincare, “Trehalose”, [online] https://www.paulaschoice.com/ingredients/ingredient-trehalose.html [Accessed Aug. 11, 2022].
[cited by applicant]
Rock et al., “Consumption of wonderful variety pomegranate juice and extract by diabetic patients increases paraoxonase 1 association with high-density lipoprotein and stimulates its catalytic activities,” J Agric Food …
[cited by applicant]
Salminen et al., “Glycolysis links p53 function with NF-κB signaling: Impact on cancer and aging process.” Journal of Cellular Physiology 224.1 (2010): 1-6.
[cited by applicant]
Škrha et al., “Minutes of the 42nd General Assembly of the European Association for the Study of Diabetes.” Diabetologia 50 (2007): S1-S538.
[cited by applicant]
Smit et al., “The hunt for natural skin whitening agents.” International Journal of Molecular Sciences 10(12), 5326-5349 (2009).
[cited by applicant]
Song et al., “Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells.” Scientific Reports 2 (2012): 362.
[cited by applicant]
Sumner et al., “Effects of pomegranate juice consumption on myocardial perfusion in patients with coronary heart disease,” Am J Cardiol, 96(6): 810-814 (2005).
[cited by applicant]
Tarnopolsky, “The mitochondrial cocktail: rationale for combined nutraceutical therapy in mitochondrial cytopathies.” Advanced Drug Delivery Reviews 60.13-14 (2008): 1561-1567.
[cited by applicant]
Trombold et al., “Ellagitannin Consumption Improves Strength Recovery 2-3 d after Eccentric Exercise”, Medicine and Science in Sports and Exercise, 42:493-498 (American College of Sports Medicine, Mar. 2010).
[cited by applicant]
Viuda-Martos et al., “Pomegranate and its Many Functional Components as Related to Human Health: A Review”, Comprehensive Reviews in Food Science and Food Safety, 9(6):635-654 (Oct. 22, 2010).
[cited by applicant]
Wang et al., “Antimelanogenic Effect of Urolithin A and Urolithin B, the Colonie Metabolites of Ellagic Acid, in B16 Melanoma Cells” Journal of Agricultural and Food Chemistry, 65: 6870-6876 (2017).
[cited by applicant]
Wang et al., “The mitophagy pathway and its implications in human diseases.” Signal Transduction and Targeted Therapy 8 (2023): 304.
[cited by applicant]
Williams et al., “Flavonoids: antioxidants or signalling molecules?.” Free Radical Biology and Medicine 36 (2004): 838-849.
[cited by applicant]